Burden of Human Papillomavirus Infection in Latin America

Burden of Human Papillomavirus (HPV) Infection and HPV- Related Disease in Latin America and the Caribbean, and Health and Economic Outcomes of HPV Vaccination in Selected Countries in Latin America

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.

The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus-like-particle vaccine has been shown to be 95-100% effective in preventing HPV 6/11/16/18-related cervical and genital disease in women naive to vaccine HPV types. A total of 6,004 female subjects aged 9-24 were recruited from Brazil, Mexico, Colomb...

Association between Human Papillomavirus Infection and Risk of Prostate Cancer

  Human papillomavirus (HPV) is one of the most common causes of sexually transmitted diseases worldwide and is the etiological agent of cervical and other anogenital malignancies. Since HPVs have been shown to possess oncogenic potential, an association between HPV infection and prostatic cancer (PCa) has been suggested. There are conflicting reports on the impact of HPV infection on the deve...

Assessment of the Association between Human Papillomavirus Infection and Breast Carcinoma

Background and Objectives: Breast cancer is the most common malignancy in women throughout the world. There are controversial reports on the role of human papillomavirus (HPV) infection in breast carcinogenesis. The aim of this study was to assess the presence of HPV-DNA in invasive breast carcinoma to determine the association between HPV infection and breast carcinoma. Methods: The study inc...

Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men.

BACKGROUND In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. METHODS A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, ...